Nephros Inc Dossier - Source-backed chat

Nephros Inc

NEPHNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.33

Intrinsic Value $3.22median of 5 methods · middle span $2-$10based on filings through 30 Jun 2026

Market Price $3.67Price as of 1 Oct 2026

Near fair valueIntrinsic value is 12% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $39.9M

Enterprise Value $35.2M

Shares Outstanding 11.3M diluted

Moat Rating Wide

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Nephros Inc. is successfully transitioning from a pure-play medical filtration supplier to a diversified water safety technology leader. Despite near-term gross margin compression driven by tariffs on Italian imports and a shift toward commercial product mixes, the company has achieved consecutive quarters of profitability and crossed the $5 million quarterly revenue milestone in Q1 2026. Its highly recurring consumable-based business model, combined with strategic expansions into commercial water applications and the launch of the Nephros Water Institute, provides a scalable, service-driven foundation for long-term growth.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.75

Mean target$6.25

High · most bullish analyst$8.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.0010%

Persistent tariff pressures, unfavorable foreign exchange fluctuations, and a faster-than-expected decline in high-margin emergency response orders compress gross margins below 55%. Increased SG&A and R&D investments outpace top-line growth, pushing the company back into net losses.

Base CaseCentral scenario

$6.0060%

Nephros maintains steady programmatic revenue growth of 10-15% in its core medical markets while gradually scaling its commercial footprint. Gross margins stabilize in the high-50s as the 10% tariff rate remains in effect, allowing the company to maintain thin but consistent profitability and positive adjusted EBITDA.

Bull CaseUpside scenario

$8.0030%

Rapid adoption of commercial filtration solutions and successful mitigation of tariff pressures (including potential recovery of $646k in past tariffs) drive gross margins back above 60%. Programmatic reorders in healthcare and dialysis settings accelerate, leading to sustained double-digit top-line growth and significant operating leverage.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Consumable-driven recurring revenue model with high customer retention in critical healthcare and dialysis settings.
Strong regulatory moat with multiple FDA 510(k) clearances for medical-grade water filtration.
Debt-free balance sheet with approximately $4.0 million in cash as of March 31, 2026.
Strategic expansion into large addressable commercial markets (food service, hospitality, convenience stores).

Key Investment Risks

Gross margin vulnerability to import tariffs (specifically on products manufactured by Medica S.p.A. in Italy).
High customer concentration and reliance on hospital capital/operating budgets.
Potential volatility in emergency response orders which can cause unpredictable quarterly revenue fluctuations.

Thesis Invalidation Triggers

Gross margin dropping below 53% on a sustained basis.
Loss of key FDA clearances or regulatory non-compliance at manufacturing partner facilities.
A reversal of the positive net income trend leading to significant cash burn that threatens the debt-free status.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.